Litcius/Paper detail

A drug discovery platform to identify compounds that inhibit EGFR triple mutants

Punit Saraon, Jamie Snider, Yannis Kalaidzidis, Leanne Wybenga-Groot, Konstantin Weiss, Ankit Rai, Nikolina Radulovich, Luka Drecun, Nika Vučković, Adriana Vučetić, Victoria Wong, Brigitte L. Thériault, Nhu‐An Pham, Jin H. Park, Alessandro Datti, Jenny Wang, Shivanthy Pathmanathan, Farzaneh Aboualizadeh, Anna Lyakisheva, Zhong Yao, Yuhui Wang, Babu Joseph, Asma M. Aman, Michael F. Moran, Michaël Prakesch, Gennady Poda, Richard Marcellus, David Uehling, Miroslav Samaržija, Marko Jakopović, Ming‐Sound Tsao, Frances A. Shepherd, Adrian G. Sacher, Natasha B. Leighl, Anna Akhmanova, Rima Al‐awar, Marino Zerial, Igor Štagljar

2020Nature Chemical Biology38 citationsDOIOpen Access PDF

Topics & Concepts

Receptor tyrosine kinaseDrug discoveryEpidermal growth factor receptorTyrosine kinaseBiologyMutantTransmembrane proteinIn vitroHigh-throughput screeningComputational biologyReceptorPharmacologyCell biologyCancer researchBiochemistryGeneMonoclonal and Polyclonal Antibodies ResearchReceptor Mechanisms and SignalingProtein Degradation and Inhibitors
A drug discovery platform to identify compounds that inhibit EGFR triple mutants | Litcius